Flexibility in Cell Targeting by Pseudotyping Lentiviral Vectors

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 614)

Abstract

Lentiviral vectors have become an important research tool and have just entered into clinical trials. As wild-type lentiviruses engage specific receptors that have limited tropism, most investigators have replaced the endogenous envelope glycoprotein with an alternative envelope. Such pseudotyped vectors have the potential to infect a wide variety of cell types and species. Alternatively, selection of certain viral envelope glycoproteins may also facilitate cell targeting to enhance directed gene transfer. We describe the method for generating pseudotyped vector and provide information regarding available pseudotypes and their respective target tissues.

Key words

Lentiviral vectors Pseudotyping Vesicular stomatitis Virus G Protein Glycoprotein Tropism 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The author is supported in part by the Indiana Genomics Initiative (INGEN). Indiana University is the site of the NHLBI Gene Therapy Resources Program (HHSN26820078204) and the NCRR National Gene Vector Biorepository (P40 RR024928).

References

  1. 1.
    Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M (1996). Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U.S.A. 93, 15266-71.PubMedCrossRefGoogle Scholar
  2. 2.
    Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ (1998). Minimal requirement of a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72, 811-6.PubMedGoogle Scholar
  3. 3.
    Sutton RE, Wu HTM, Rigg R, Bohnlein E, Brown PO (1998). Human immunodeficiency virus type 1 vectors efficiently transduce huma hematopoietic stem cells. J. Virol. 72, 5781-8.PubMedGoogle Scholar
  4. 4.
    Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996). In vivo gene delivery an stable transducion of nondividing cells by a lentiviral vector. Science 272, 263-7.PubMedCrossRefGoogle Scholar
  5. 5.
    Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998). Development of a self-inactivating lentivurs vector. J. Virol. 72, 8150-57.PubMedGoogle Scholar
  6. 6.
    Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998). Self-inactivating lentivirus vector for safe and efficiency in vivo gene delivery. J. Virol. 72, 9873-80.PubMedGoogle Scholar
  7. 7.
    Corbeau P, Kraus G, Wong-Staal F (1998). Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system. Gene Ther. 5, 99-104.PubMedCrossRefGoogle Scholar
  8. 8.
    Sadaie MR, Zamani M, Whang S, Sistron N, Arya SK (1998). Towards developing HIV-2 lentivirus-based retroviral vectors for gene therapy, dual gene expression in the context of HIV-2 LTR and Tat. J. Med. Virol. 54, 118-28.PubMedCrossRefGoogle Scholar
  9. 9.
    Negre D, Duisit G, Mangeot PE, Moullier P, Darlix JL, Cosset FL (2002). Lentiviral vectors derived from simian immunodeficiency virus. Curr. Top. Microbiol. Immunol. 261, 53-74.PubMedCrossRefGoogle Scholar
  10. 10.
    Gilbert JR, Wong-Staal F (2001). HIV-2 and SIV vector systems. Somat. Cell. Mol. Genet. 26, 83-98PubMedCrossRefGoogle Scholar
  11. 11.
    Poeschla EM, Wong-Staal F, Looney DJ (1998). Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4, 354-7.PubMedCrossRefGoogle Scholar
  12. 12.
    Johnston J, Power C (1999). Productive infection of human peripheral blood mononuclear cells by feline immunodeficiency virus, implications for vector development. J. Virol. 73, 2491-8.PubMedGoogle Scholar
  13. 13.
    Olsen JC (2001). EIAV, CAEV and other lentivirus vector systems. Somat. Cell. Mol. Genet. 26, 131-45.PubMedCrossRefGoogle Scholar
  14. 14.
    Mselli-Lakhal L, Favier C, Leung K, Guiguen F, Grezel D, Miossec P, Mornex JF, Narayan O, Querat G, Chebloune Y (2000). Lack of functional receptors is the only barrier that prevents caprine arthritis-encephalitis virus from infecting human cells. J. Virol. 74, 8343-8.PubMedCrossRefGoogle Scholar
  15. 15.
    Berkowitz R, Ilves H, Lin WY, Eckert K, Coward A, Tamaki S, Veres G, Plavec I (2001). Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J. Virol. 75, 3371-82.PubMedCrossRefGoogle Scholar
  16. 16.
    Metharom P, Takyar S, Xia HH, Ellem KA, Macmillan J, Shepherd RW, Wilcox GE, Wei MQ (2000). Novel bovine lentiviral vectors based on Jembrana disease virus. J. Gene Med. 2, 176-85.PubMedCrossRefGoogle Scholar
  17. 17.
    Berkowitz RD, Ilves H, Plavec I, Veres G (2001). Gene transfer systems derived from Visna virus, analysis of virus production and infectivity. Virology 279, 116-29.PubMedCrossRefGoogle Scholar
  18. 18.
    Zavada J (1972). Pseudotypes of vesicular stomatitis virus with the coat of murine leukaemia and of avian myeloblastosis viruses. J. Gen. Virol. 15, 183-91.PubMedCrossRefGoogle Scholar
  19. 19.
    Huang AS, Besmer P, Chu L, Baltimore D (1973). Growth of pseudotypes of vesicular stomatitis virus with N-tropic murine leukemia virus coats in cells resistant to N-tropic viruses. J. Virol. 12, 659-62.PubMedGoogle Scholar
  20. 20.
    Choppin PW, Compans RW (1970). Phenotypic mixing of envelope proteins of the parainfluenza virus SV5 and vesicular stomatitis virus. J. Virol. 5, 609-16.PubMedGoogle Scholar
  21. 21.
    Miller AD (1990). Retrovirus packaging cells. Hum. Gene Ther. 1, 5-14.PubMedCrossRefGoogle Scholar
  22. 22.
    Freed EO, Martin MA (1995). The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270, 23883-6.PubMedCrossRefGoogle Scholar
  23. 23.
    Beausejour Y, Tremblay MJ (2004). Envelope glycoproteins are not required for insertion of host ICAM-1 into human immunodeficiency virus type 1 and ICAM-1-bearing viruses are still infectious despite a suboptimal level of trimeric envelope proteins. Virology 324, 165-72.CrossRefGoogle Scholar
  24. 24.
    Pickl WF, Pimentel-Muinos FX, Seed B (2001). Lipid rafts and pseudotyping. J. Virol. 75, 7175-83.PubMedCrossRefGoogle Scholar
  25. 25.
    Dragic T (2001). An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 82, 1807-14.PubMedGoogle Scholar
  26. 26.
    Kazmierski WM, Kenakin TP, Gudmundsson KS, (2006). Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. Chem. Biol. Drug Des. 67, 13-26.PubMedCrossRefGoogle Scholar
  27. 27.
    Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-7.PubMedCrossRefGoogle Scholar
  28. 28.
    Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M (1996). Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U.S.A. 93, 15266-71.PubMedCrossRefGoogle Scholar
  29. 29.
    Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS (1996). High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70, 2581-5.PubMedGoogle Scholar
  30. 30.
    Steven AC, Spear PG (2006). Biochemistry. Viral glycoproteins and an evolutionary conundrum. Science 313, 177-8.PubMedCrossRefGoogle Scholar
  31. 31.
    Sharkey CM, North CL, Kuhn RJ, Sanders DA (2001). Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J. Virol. 75, 2653-9.PubMedCrossRefGoogle Scholar
  32. 32.
    Picard-Maureau M, Jarmy G, Berg A, Rethwilm A, Lindemann D (2003). Foamy virus envelope glycoprotein-mediated entry involves a pH-dependent fusion process. J. Virol. 77, 4722-30.PubMedCrossRefGoogle Scholar
  33. 33.
    Bertrand P, Cote M, Zheng YM, Albritton LM, Liu SL (2008). Jaagsiekte sheep retrovirus utilizes a pH-dependent endocytosis pathway for entry. J. Virol. 82, 2555-9.PubMedCrossRefGoogle Scholar
  34. 34.
    Stein BS, Gowda SD, Lifson JD, Penhallow RC, Bensch KG, Engleman EG (1987). pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell 49, 659-68.PubMedCrossRefGoogle Scholar
  35. 35.
    Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL (2003). Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278, 41624-30.PubMedCrossRefGoogle Scholar
  36. 36.
    White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper R (2007). Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob. Agents Chemother. 51, 2293-303.PubMedCrossRefGoogle Scholar
  37. 37.
    Burns JC, Friedmann T, Driever W, Burrascano M, Yee J-K (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors, concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90, 8033-37.PubMedCrossRefGoogle Scholar
  38. 38.
    Takeuchi Y, Simpson G, Vile RG, Weiss RA, Collins MK (1992). Retroviral pseudotypes produced by rescue of a Moloney murine leukemia virus vector by C-type, but not D-type, retroviruses. Virology 186, 792-4.PubMedCrossRefGoogle Scholar
  39. 39.
    Lindemann D, Bock M, Schweizer M, Rethwilm A (1997). Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J. Virol. 71, 4815-20.PubMedGoogle Scholar
  40. 40.
    Mammano F, Salvatori F, Indraccolo S, De Rossi A, Chieco-Bianchi L, Gottlinger HG (1997). Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. J. Virol. 71, 3341-45.PubMedGoogle Scholar
  41. 41.
    Stitz J, Buchholz CJ, Engelstadter M, Uckert W, Bleimer U, Schmitt I, Cichutek K (2000). Lentiviral vectors pseudotyped with envelope glycoproteins derived from Gibbonr Ape Leukemia Virus and Murine Leukemia Virus 10A1. Virology 273, 16-20.PubMedCrossRefGoogle Scholar
  42. 42.
    Sandrin V, Boson B, Salmon P, Gay W, Negre D, Le Grand R, Trono D, Cosset F (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100, 823-32.PubMedCrossRefGoogle Scholar
  43. 43.
    Di Nunzio F, Piovani B, Cosset F-L, Malivio F, Stornaiuolo A (2007). Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein. Hum. Gene Ther. 18, 811-20.PubMedCrossRefGoogle Scholar
  44. 44.
    Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff J, Hargrove P, Vanin EF, Nienhuis AW (2002). Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hemaopoietic cells from human blood. Mol. Ther. 5, 242-51.PubMedCrossRefGoogle Scholar
  45. 45.
    Relander T, Johansson M, Olsson K, Ikeda Y, Takeuchi Y, Collins M, Richter J (2002). Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, RD114-pseudotyped HIV-1 based vectors from stable producer cells. Mol. Ther. 11, 452-9.CrossRefGoogle Scholar
  46. 46.
    Sharkey CM, North CL, Kuhn RJ, Sanders DA (2001). Ross River virus glycoprotein-pseudotyped retroviruses and stable cell lines for their production. J. Virol. 75, 2653-59.PubMedCrossRefGoogle Scholar
  47. 47.
    Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, et al. (2002). In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River virus glycoproteins. J. Virol. 76, 9378-88.PubMedCrossRefGoogle Scholar
  48. 48.
    Kahl CA, Marsh J, Fyffe J, Sanders DA, Cornetta K (2004). Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J. Virol. 78, 1421-30.PubMedCrossRefGoogle Scholar
  49. 49.
    Kang Y, S. SC, Heth JA, Sinn PL, Penisten AK, Stabler PD, Ratliff KL, Shen H, Barker CK, Martins I, et al. (2002). In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J. Virol. 76, 9378-88.PubMedCrossRefGoogle Scholar
  50. 50.
    Kahl CA, Pollok K, Haneline LS, Cornetta K (2005). Lentiviral vectors pseudotyped with glycoproteins from Ross River and vesicular stomatitis viruses, variable transduction related to cell type and culture conditions. Mol. Ther. 11, 470-82.PubMedCrossRefGoogle Scholar
  51. 51.
    Funke S, Maisner A, Muhlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ (2008). Targeted cell entry of lentiviral vectors. Mol. Ther. 16, 1427-36.PubMedCrossRefGoogle Scholar
  52. 52.
    Sinn PL, Penisten AK, Burnight ER, Hickey MA, Williams G, McCoy DM, Mallampalli RK, McCray Jr PB (2005). Gene transfer to respiratory epithelia with lentivirus pseudotyped with Jaagsickte Sheep Retrovirus envelope glycoprotein. Hum. Gene Ther. 16, 479-88.PubMedCrossRefGoogle Scholar
  53. 53.
    Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998). A third generation lentivirus with a conditional packaging system. J. Virol. 72, 8463-71.PubMedGoogle Scholar
  54. 54.
    Kahl CA, Marsh J, Fyffe J, Sanders DA, Cornetta K (2004). Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J. Virol. 78, 1421-30.PubMedCrossRefGoogle Scholar
  55. 55.
    Mochizuki H, Schwartz JP, Tanaka K, Brady RO, Reiser J (1998). High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol. 72, 8873-83.PubMedGoogle Scholar
  56. 56.
    Desmaris N, Bosch A, Salaun C, Petit C, Prevost MC, Tordo N, Perrin P, Schwartz O, de Rocquigny H, Heard JM (2001). Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol. Ther. 4, 149-56.PubMedCrossRefGoogle Scholar
  57. 57.
    Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P, Vanin EF, Nienhuis AW (2002). Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol. Ther. 5, 242-51.PubMedCrossRefGoogle Scholar
  58. 58.
    Watson DJ, Kobinger GP, Passini MA, Wilson JM, Wolfe JH, (2002). Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 5, 528-37.PubMedCrossRefGoogle Scholar
  59. 59.
    Poeschla E, Gilbert J, Li X, Huang S, Ho A, Wong-Staal F (1998). Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. J. Virol. 72, 6527-36.PubMedGoogle Scholar
  60. 60.
    Duisit G, Conrath H, Saleun S, Folliot S, Provost N, Cosset FL, Sandrin V, Moullier P, Rolling F (2002). Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat. Mol. Ther. 6, 446-54.PubMedCrossRefGoogle Scholar
  61. 61.
    Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, Mazarakis N (1999). Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808-18.PubMedCrossRefGoogle Scholar
  62. 62.
    Wong LF, Azzouz M, Walmsley LE, Askham Z, Wilkes FJ, Mitrophanous KA, Kingsman SM, Mazarakis ND (2004). Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 9, 101-11.PubMedCrossRefGoogle Scholar
  63. 63.
    Olsen JC (1998). Gene transfer vectors derived from equine infectious anemia virus. Gene Ther. 5, 1481-87.PubMedCrossRefGoogle Scholar
  64. 64.
    McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC (2006). Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 13, 715-24.PubMedCrossRefGoogle Scholar
  65. 65.
    Sandrin V, Boson B, Salmon P, Gay W, Negre D, Le Grand R, Trono D, Cosset FL (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100, 823-32.PubMedCrossRefGoogle Scholar
  66. 66.
    Strang BL, Takeuchi Y, Relander T, Richter J, Bailey R, Sanders DA, Collins MK, Ikeda Y (2005). Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. J. Virol. 79, 1765-71.PubMedCrossRefGoogle Scholar
  67. 67.
    Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, et al. (2002). In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J. Virol. 76, 9378-88.PubMedCrossRefGoogle Scholar
  68. 68.
    Kolokoltsov AA, Weaver SC, Davey RA (2005). Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. J. Virol. 79, 756-63.PubMedCrossRefGoogle Scholar
  69. 69.
    Poluri A, Ainsworth R, Weaver SC, Sutton RE (2008). Functional Pseudotyping of Human Immunodeficiency Virus Type 1 Vectors by Western Equine Encephalitis Virus Envelope Glycoprotein. J. Virol. 82, 12580-4.PubMedCrossRefGoogle Scholar
  70. 70.
    Morizono K, Bristol G, Xie YM, Kung SK, Chen IS (2001). Antibody-directed targeting of retroviral vectors via cell surface antigens. J. Virol. 75, 8016-20.PubMedCrossRefGoogle Scholar
  71. 71.
    Sinn PL, Hickey MA, Staber PD, Dylla DE, Jeffers SA, Davidson BL, Sanders DA, McCray Jr PB (2003). Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J. Virol. 77, 5902-10.PubMedCrossRefGoogle Scholar
  72. 72.
    Strang BL, Ikeda Y, Cosset FL, Collins MK, Takeuchi Y (2004). Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Ther. 11, 591-8.PubMedCrossRefGoogle Scholar
  73. 73.
    Christodoulopoulos I, Cannon PM (2001). Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J. Virol. 75, 4129-38.PubMedCrossRefGoogle Scholar
  74. 74.
    Di Nunzio F, Piovani B, Cosset FL, Mavilio F, Stornaiuolo A (2007). Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein. Hum. Gene Ther. 18, 811-20.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang XY, La Russa VF, Reiser J (2004). Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J. Virol. 78, 1219-29.PubMedCrossRefGoogle Scholar
  76. 76.
    Schambach A, Galla M, Modlich U, Will E, Chandra S, Reeves L, Colbert M, Williams DA, von Kalle C, Baum C (2006). Lentiviral vectors pseudotyped with murine ecotropic envelope, increased biosafety and convenience in preclinical research. Exp. Hematol. 34, 588-92.PubMedCrossRefGoogle Scholar
  77. 77.
    Landau NR, Page KA, Littman DR (1991). Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J. Virol. 65, 162, 9.PubMedGoogle Scholar
  78. 78.
    Liu SL, Halbert CL, Miller AD (2004). Jaagsiekte sheep retrovirus envelope efficiently pseudotypes human immunodeficiency virus type 1-based lentiviral vectors. J. Virol. 78, 2642-47.PubMedCrossRefGoogle Scholar
  79. 79.
    Lewis BC, Chinnasamy N, Morgan RA, Varmus HE (2001). Development of an avian leukosis-sarcoma virus subgroup A pseudotyped lentiviral vector. J. Virol. 75, 9339-44.PubMedCrossRefGoogle Scholar
  80. 80.
    Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, Cosset FL, Verhoeyen E (2008). Stable transduction of quiescent T-cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112, 4843-52.PubMedCrossRefGoogle Scholar
  81. 81.
    Jung C, Grzybowski BN, Tong S, Cheng L, Compans RW, Le Doux JM (2004). Lentiviral vectors pseudotyped with envelope glycoproteins derived from human parainfluenza virus type 3. Biotechnol. Prog. 20, 1810-16.PubMedCrossRefGoogle Scholar
  82. 82.
    Kowolik CM, Yee JK (2002). Preferential transduction of human hepatocytes with lentiviral vectors pseudotyped by Sendai virus F protein. Mol. Ther. 5, 762-9.PubMedCrossRefGoogle Scholar
  83. 83.
    Kobayashi M, Iida A, Ueda Y, Hasegawa M (2003). Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J. Virol. 77, 2607-14.PubMedCrossRefGoogle Scholar
  84. 84.
    Kobinger GP, Deng S, Louboutin JP, Vatamaniuk M ,Matschinsky F, Markmann JF, Raper SE, Wilson JM (2004). Transduction of human islets with pseudotyped lentiviral vectors. Hum. Gene Ther. 15, 211-9.PubMedCrossRefGoogle Scholar
  85. 85.
    Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA (2003). Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U.S.A. 100, 7271-6.PubMedCrossRefGoogle Scholar
  86. 86.
    Kumar M, Bradow BP, Zimmerberg J (2003). Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64. Hum. Gene Ther. 14, 67-77.PubMedCrossRefGoogle Scholar
  87. 87.
    Kobinger GP, Weiner DJ, Yu QC, Wilson JM (2001). Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19, 225-30.PubMedCrossRefGoogle Scholar
  88. 88.
    Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, Lee DC, Wilkes F, Mitrophanous KA, Kingsman SM, Burghes AH, Mazarakis ND (2004). Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest. 114, 1726-31.PubMedGoogle Scholar
  89. 89.
    Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND (2004). VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 341-7.CrossRefGoogle Scholar
  90. 90.
    Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641-49.PubMedGoogle Scholar
  91. 91.
    Stein CS, Martins I, Davidson BL (2005). The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. Mol. Ther. 11, 382-9.PubMedCrossRefGoogle Scholar
  92. 92.
    Miletic H, Fischer YH, Neumann H, Hans V, Stenzel W, Giroglou T, Hermann M, Deckert M, Von Laer D (2004). Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins. Hum. Gene Ther 15, 1091-100.PubMedCrossRefGoogle Scholar
  93. 93.
    Relander T, Johansson M, Olsson K, Ikeda Y, Takeuchi Y, Collins M, Richter J (2004). Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol. Ther. 11, 452-9.CrossRefGoogle Scholar
  94. 94.
    MacKenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S, Wilson JM, Verma IM, Flake AW (2002). Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol. Ther. 6, 349-58.PubMedCrossRefGoogle Scholar
  95. 95.
    Auricchio A, Kobinger G, Anand V, Hildinger M, O’Connor E, Maguire AM, Wilson JM, Bennett J (2001). Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics, the retina as a model. Hum. Mol. Genet. 10, 3075-81.PubMedCrossRefGoogle Scholar
  96. 96.
    Park F (2003). Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in hemophilia A mice. Hum. Gene Ther. 14, 1489-94.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisUSA

Personalised recommendations